trending Market Intelligence /marketintelligence/en/news-insights/trending/whGimH2K93YoI5NrdN5EmQ2 content esgSubNav
In This List

Vascular Biogenics' VB-111 improves overall survival in brain cancer patients

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Vascular Biogenics' VB-111 improves overall survival in brain cancer patients

Longer treatment by Vascular Biogenics Ltd.'s VB-111 showed durable tumor regression and attenuation of tumor growth in patients with recurrent glioblastoma, an aggressive cancer which begins in the brain.

The second cohort of a phase 2 trial of the drug in combination with Genentech's Avastin demonstrated favorable anti-tumor activity in terms of regression rate and overall survival following treatment through progression, as compared to a brief exposure to VB-111 with subsequent Avastin monotherapy and to historical data of Avastin monotherapy. The responses were similar for VB-111 monotherapy, including a patient who remains in complete remission after more than three years.

The company is conducting a phase 3 study comparing VB-111 in combination with Avastin to Avastin alone for the said cancer type in the U.S., Canada and Israel.

Genentech is a subsidiary of Roche Holding Ltd.